Compare KRYS & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRYS | FHI |
|---|---|---|
| Founded | 2015 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 4.0B |
| IPO Year | 2017 | N/A |
| Metric | KRYS | FHI |
|---|---|---|
| Price | $244.20 | $52.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $214.22 | $49.00 |
| AVG Volume (30 Days) | 277.7K | ★ 598.3K |
| Earning Date | 11-03-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.62% |
| EPS Growth | ★ 275.72 | 50.93 |
| EPS | ★ 6.66 | 4.77 |
| Revenue | $373,164,000.00 | ★ $1,742,513,000.00 |
| Revenue This Year | $36.14 | $10.23 |
| Revenue Next Year | $41.80 | $6.95 |
| P/E Ratio | $36.79 | ★ $10.89 |
| Revenue Growth | ★ 54.51 | 8.98 |
| 52 Week Low | $122.80 | $35.05 |
| 52 Week High | $248.60 | $54.42 |
| Indicator | KRYS | FHI |
|---|---|---|
| Relative Strength Index (RSI) | 81.72 | 63.16 |
| Support Level | $213.83 | $50.01 |
| Resistance Level | $241.65 | $51.42 |
| Average True Range (ATR) | 7.53 | 0.95 |
| MACD | 2.17 | 0.33 |
| Stochastic Oscillator | 89.34 | 83.65 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).